8-K: Renalytix Receives Draft Medicare Coverage for KidneyIntelX Tests

Renalytix has announced that the Centers for Medicare and Medicaid Services (CMS) has published a draft Local Coverage Determination (LCD) for its KidneyIntelX and kidneyintelX.dkd tests.

Summary

• Renalytix has received a draft Local Coverage Determination (LCD) from the Centers for Medicare and Medicaid Services (CMS) for its KidneyIntelX and kidneyintelX.dkd tests.
• The draft LCD specifies coverage for patients with diagnosed Type 2 diabetes and Stage 1-3b Chronic Kidney Disease.
• The established Medicare price for each test is $950.
• The draft LCD was submitted by National Government Services (NGS), a Medicare Administrative Contractor.
• A 45-day public comment period is open until March 23, 2024.
• The final LCD is expected in calendar year 2024.

Sentiment

Score: 7

Explanation: The draft LCD is a positive development, but the final outcome is still uncertain. The established price point is encouraging, but the public comment period introduces some risk.

Positives

• The draft LCD is a significant step towards Medicare coverage for Renalytix's KidneyIntelX tests.
• The established Medicare price of $950 per test provides a clear revenue opportunity.
• The draft LCD specifies coverage for a substantial patient population with Type 2 diabetes and Stage 1-3b Chronic Kidney Disease.
• The company submitted substantial peer reviewed published evidence in support of coverage of KidneyIntelX and kidneyintelX.dkd.

Negatives

• The LCD is still in draft form and subject to change based on public comments.
• The final LCD is not guaranteed and is expected in calendar year 2024, creating uncertainty.

Risks

• The final LCD may not be as favorable as the draft, potentially impacting coverage and revenue.
• The public comment period could result in changes to the proposed coverage.
• The company's reliance on novel artificial intelligence technologies carries inherent risks related to acceptance and clinical practice.
• The company has only recently commercially launched KidneyIntelX, which introduces uncertainty.

Future Outlook

The company expects the final LCD to be issued in calendar year 2024, following the review of public comments.

Management Comments

• The company believes that based on the evidence, and the FDAs De Novo Marketing Authorization for the kidneyintelX.dkd test, that there was a strong basis for NGS determining that these tests are reasonable and necessary for Medicare beneficiaries.

Industry Context

This announcement is significant for the in-vitro diagnostics industry, as it represents a major step towards reimbursement for novel diagnostic tests. It also highlights the growing focus on early detection and management of chronic kidney disease.

Comparison to Industry Standards

• The $950 price point for KidneyIntelX is in line with other advanced diagnostic tests, but the final reimbursement will depend on the final LCD.
• Other companies in the diagnostics space, such as Exact Sciences and Guardant Health, have also faced similar challenges in securing Medicare coverage for their tests.
• The 45-day public comment period is standard practice for CMS, and the final LCD will be a key indicator of the test's market potential.

Stakeholder Impact

• Shareholders will view the draft LCD as a positive step towards revenue generation.
• Patients with Type 2 diabetes and Stage 1-3b Chronic Kidney Disease may benefit from increased access to KidneyIntelX testing.
• Healthcare providers may have a new tool for assessing kidney disease risk.

Next Steps

• The company will monitor the public comment period and engage with CMS as needed.
• The company will await the final LCD decision from CMS, expected in calendar year 2024.

Key Dates

Keywords

KidneyIntelX, kidneyintelX.dkd, Medicare, CMS, Local Coverage Determination, LCD, Chronic Kidney Disease, Type 2 Diabetes, bioprognosis, in-vitro diagnostics